Hologic (HOLX)

• Market cap: $13.1B
• 1 day: -0.27%
• 5 days: -0.46%
• 1 month: -5.78%
• 3 months: -19.36%
• 6 months: -28.28%
• Year to date: -18.87%
• 1 year: -23.19%
• 5 years: 16.17%
• 10 years: 72.50%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Employees: 7,063

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

9% more call options, than puts

Call options by funds: $39.4M | Put options by funds: $36.2M

5% more first-time investments, than exits

New positions opened: 89 | Existing positions closed: 85

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

0.24% less ownership

Funds ownership: 97.22% [Q3] → 96.98% (-0.24%) [Q4]

1% less funds holding

Funds holding: 711 [Q3] → 702 (-9) [Q4]

12% less capital invested

Capital invested by funds: $18.4B [Q3] → $16.2B (-$2.14B) [Q4]

12% less repeat investments, than reductions

Existing positions increased: 249 | Existing positions reduced: 283

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $70 20% upside
• Avg. target: $80 37% upside
• High target: $90 55% upside

6 analyst ratings

• positive: 2 33%
• neutral: 4 67%
• negative: 0 0%

Citigroup Patrick Donnelly 27% 1-year accuracy 8 / 30 met price target	20% upside $70	Neutral Maintained	4 Mar 2025
Raymond James Andrew Cooper 28% 1-year accuracy 5 / 18 met price target	55% upside $90	Outperform Reiterated	6 Feb 2025
RBC Capital Conor McNamara 17% 1-year accuracy 7 / 41 met price target	46% upside $85	Sector Perform Maintained	6 Feb 2025
Evercore ISI Group Vijay Kumar 30% 1-year accuracy 12 / 40 met price target	25% upside $73	In-Line Maintained	6 Feb 2025
Stephens & Co. Mason Carrico 15% 1-year accuracy 4 / 26 met price target	44% upside $84	Overweight Reiterated	6 Feb 2025